Quest Diagnostics to Speak at the Merrill Lynch Health Services Investor Conference

Monday, November 26, 2007 General News J E 4
MADISON, N.J., Nov. 26 Quest DiagnosticsIncorporated (NYSE: DGX), the nation's leading provider of diagnostic testing,information and services, announced that it is scheduled to speak at theMerrill Lynch Health Services Investor Conference at the Merrill LynchHeadquarters in New York City on Tuesday, November 27, 2007. The QuestDiagnostics presentation is scheduled to begin at 10:15 a.m. Eastern Time.

During the conference, the company will reiterate its 2007 guidance forrevenues of between $6.6 billion and $6.7 billion, operating income ofapproximately 16% of revenues, and earnings per diluted share from continuingoperations of between $2.84 and $2.91 These estimates exclude $0.04 per sharein total first quarter charges associated with workforce reductions and theexpense of in-process research and development, and are before potentialadditional special charges.

The presentation will be webcast live during the conference and will beavailable to registered investors on the following site: and to thepublic on In addition, the archived webcastwill be available within 24 hours after the presentation and will remainavailable until December 12, 2007.

Quest Diagnostics is the leading provider of diagnostic testing,information and services that patients and doctors need to make betterhealthcare decisions. The company offers the broadest access to diagnostictesting services through its national network of laboratories and patientservice centers, and provides interpretive consultation through its extensivemedical and scientific staff. Quest Diagnostics is a pioneer in developinginnovative new diagnostic tests and advanced healthcare information technologysolutions that help improve patient care. Additional company information isavailable at:

The statements in this press release which are not historical facts orinformation may be forward-looking statements. These forward-lookingstatements involve risks and uncertainties that could cause actual results andoutcomes to be materially different. Certain of these risks and uncertaintiesmay include, but are not limited to, competitive environment, changes ingovernment regulations, changing relationships with customers, payers,suppliers and strategic partners and other factors described in the QuestDiagnostics Incorporated 2006 Form 10-K and subsequent SEC filings.

SOURCE Quest Diagnostics Incorporated


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Bayer CropScience, Mertec and M.S. Technologies to...
MedImmune Initiates First Clinical Trial of Monocl...